November 5, 2021
Yes, it’s big but …..
Now that we’re moving out of earnings season and headed towards the holidays it’s time to examine a developing theme. Yes, we know that analysts aren’t always the sharpest knives in the drawer, but they do know a huge market when they see one and there is no larger market in diabetes than the Type 2 patient population. Hence the reason Dexcom, Abbott, Tandem and Insulet all made a point to mention their efforts to gain access to this huge group of patients. The perception seems to be spreading that the Type 1 population is adapting . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
